FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:36:242 | Bilateral central retinal artery occlusion as the first manifestation of eosinophilic granulomatosis with polyangiitis during benralizumab therapy Benedetta Fazzi1, Elena Treppo1, Lucia Finocchio2, Maria Pillon1, Luca Quartuccio1 | 1Clinica di Reumatologia, Dipartimento di Medicina, Presidio Ospedaliero Universitario Santa Maria della Misericordia, Udine; 2SOC Oculistica, Presidio Ospedaliero Universitario Santa Maria della Misericordia, ASUFC, Udine, Italy
73 -
PO:14:206 | Factors impacting subjective cognitive impairment in systemic lupus erythematosus patients: clearing away the lupus brain fog Elisabetta Chessa1, Marta Paola Pireddu2, Fabio Congiu2, Giulia Rizzo2, Cristina Serafini3, Elena Ragusa2, Alberto Cauli1|2, Matteo Piga1|2. | 1SC Reumatologia- AOU Cagliari, Cagliari, Italy; 2Dipartimento di Scienze Mediche e Sanità Pubblica, Università di Cagliari, Cagliari, Italy; 3PO Sirai - Unità di Nefrologia e Dialisi, Carbonia (CA), Italy.
70 -
PO:33:203 | Efficacy and safety of rituximab in eosinophilic fasciitis: report of three cases and systematic literature review Andrea Benini1, Beatrice Moccaldi1, Marco Binda1, Anna Cuberli1, Mariangela Favaro1, Andrea Doria1, Elisabetta Zanatta1 | 1UOC Reumatologia, Azienda Ospedale, Università di Padova, Italy
84 -
CO:06:3 | Clinical and laboratory markers for distinguishing VEXAS from Schnitzler's syndrome in male patients with skin involvement: insights from the International AIDA Network Registries Valeria Caggiano1, Jessica Sbalchiero1, Micol Frassi2, Andrea Hinojosa-Azaola3, Francesca Crisafulli2, Franco Franceschini2, Paolo Sfriso4, Sara Bindoli4, José Hernández-Rodríguez5, Henrique A. Mayrink Giardini6, Giuseppe Lopalco7, Florenzo Iannone7, Ombretta Viapiana8, Amato De Paulis9, Lorenzo Dagna10, Antonio Gidaro11, Serena Bugatti12, Matteo Piga13, Fabrizio Conti14, Rosetta Vitetta15, Cecilia Chighizola16, Marcello Govoni17, Giacomo Emmi18, Paola Triggianese19, Carmelo Gurnari19, Bruno Frediani1, Claudia Fabiani1, Luca Cantarini1, Antonio Vitale1, for the AIDA Network1 | 1Department of Medical Sciences, Surgery and Neurosciences, University of Siena; 2University of Brescia, Italy; 3Department of Immunology and Rheumatology, Mexico City, Mexico; 4Rheumatology Unit, University of Padova, Italy; 5Clinical Unit of Autoinflammatory Diseases, Hospital Clínic of Barcelona, Spain; 6Rheumatology Division, Universidade de São Paulo, Brazil; 7University of Bari; 8Rheumatology Unit, University and Azienda Ospedaliera Universitaria Integrata of Verona; 9University of Napoli "Federico II"; 10Università Vita-Salute San Raffaele, Milano; 11Luigi Sacco Hospital, University of Milano; 12Università di Pavia; 13University and AOU of Cagliari; 14AOU Policlinico Umberto I, Sapienza University of Rome; 15Unit of Rheumatology, ASL Sant' Andrea Hospital, Vercelli; 16University of Milano; 17Azienda Ospedaliero-Universitaria S. Anna, Ferrara; 18University of Trieste; 19University of Rome-Tor Vergata, Rome, Italy.
93 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
68
